SF
ALNY icon

Summit Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Summit Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,456
Closed -$579K – 1402
2025
Q4 		$579K Buy
+1,456
New +$644K 0.01% 838

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Financial's ALNY Position: Q1 2026 in Review

Summit Financial sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,456 shares — an estimated $579K sold.

Summit Financial first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $579K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Summit Financial reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Summit Financial sold 1,456 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $579K.
  • Summit Financial first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Summit Financial's Alnylam Pharmaceuticals position peaked at $579K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Summit Financial's 13F filing for Q1 2026, filed 15 May 2026.